The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Pharmaceutical Technology on MSN5d
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...
AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
8d
AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.
Metronidazole is added if anaerobic activity ... be redosed if the bariatric surgery exceeds two half-lives of the drug from the time the first dose was administered or if the operation exceeds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback